The Advertising Standards Authority (ASA) is now investigating Reckitt Benckiser (the makers of Nurofen) for potentially misleading customers in the UK after the company was banned from selling products in Australia.
The UK’s Advertising Standards Authority (ASA) has now confirmed it is is investigating 12 complaints (initially received in February 2015) about a television advert for Nurofen Express. While the product name ‘Nurofen Express’ is valid, due to the fact that liquid formulations work more quickly than the Nurofen tablet formulation, the ASA is determining whether the advert could have misled the public because it appears to imply that the product directly targets headaches.
According to The Independent, the ASA said:
Complainants have challenged whether the ad is misleading because it implies the product directly targets muscles in the head. They’ve also challenged whether the claim ‘gives you faster headache relief than standard paracetamol or ibuprofen’ is misleading… The advertiser is providing evidence to substantiate its claims. We’re carefully assessing that and we’ll publish our findings in due course.
The company initially landed itself in hot water after it was banned in Australia from selling several versions of its product marketed under different names such as Nurofen Back Pain, Period Pain, Migraine Pain and Tension Headache. The Australian court found that these “specific pain” products had the same ingredients as in Nurofen’s standard pills, but were nearly twice as expensive.
Reckitt Benckiser has “engaged in misleading conduct” by labelling them for different ailments, the Federal Court ruled.
Dr Aomesh Bhatt, medical affairs director at Reckitt Benckiser made the following claim in The Guardian:
The Nurofen specific-pain range was launched with an intention to help consumers navigate their pain relief options, particularly within the grocery environment where there is no healthcare professional to assist decision making.
The Medicines and Healthcare Regulatory Products Agency (MHRA), whose role it is to police pharmaceutical marketing and labels on product packaging, says it is aware of the Australian ruling but has not received any complaints about the way in which Nurofen products are packaged in the UK. It will be interesting to see whether the ASA ruling changes this.
Featured image via Flickr Creative Commons
We need your help to keep speaking the truth
Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.
Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.
We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.
In return, you get:
* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop
Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.
With your help we can continue:
* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do
We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?